SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after extending its post-IPO slide to fresh lows, with traders citing upcoming share unlocks and insider selling, a TD Cowen price-target cut, and concerns about OpenAI concentration and the companys ability to scale. Bearish sentiment dominates, though some investors see the decline as overdone and point to its cash position, backlog, and wafer-scale AI technology as reasons to buy.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a steep selloff alongside other AI infrastructure and neocloud stocks, amid concerns about financing needs, debt exposure and whether AI spending will generate adequate returns. Traders are divided between viewing the decline as an oversold buying opportunity with bounce or short-squeeze potential and warning that rebounds may fade as sector-wide selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS CEO Angelos Stergious anniversary post about the companys next chapter with GPS and SLS009 has fueled speculation about upcoming clinical news or a buyout, though some traders see it as a routine reassurance. Discussion chiefly centers on the blinded Phase 3 REGAL trial, whose final analysis is triggered at 80 deaths; the last reported count was 78, and traders disagree on whether the prolonged wait is encouraging or simply leaves the outcome uncertain.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being linked to Trumps declining approval and the approaching midterms, with traders treating the stock as highly exposed to political sentiment. Bearish discussion dominates, citing weak business fundamentals and Truth Social engagement, though some traders see the selloff as a buying opportunity.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention ahead of its Q3 earnings report, with traders weighing the results against scrutiny of the 6.2L engine recall fix after reports of failures following repairs. The community is debating whether potential warranty and legal costs could overshadow the quarter, while options positioning appears mixed.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United CEO Scott Kirbys support for a wealth tax and inheritance taxes approaching 100% has prompted angry calls for a boycott, though some traders remain focused on the airlines upcoming quarterly results. Ahead of earnings, discussion also weighs bullish expectations against concerns that higher fuel costs and economic uncertainty could pressure margins.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT results are driving attention: the experimental RNAi treatment showed substantial tau reduction after subcutaneous dosing, prompting discussion of potential blood-brain barrier delivery and broader CNS-platform validation. Traders largely view the data as encouraging but debate its significance because it is an early biomarker result, while many are frustrated that the share-price reaction has been muted.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a sharp AI and semiconductor selloff, as traders debate whether AI infrastructure demand can justify spending and valuations or whether debt and financing risksparticularly around CoreWeavesignal deeper trouble. Bulls cite continued demand and upcoming company updates, while skeptics point to weak price action and uncertain returns on AI capex.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas Q3 earnings miss and reduced full-year profit outlook, attributed to sharply higher fuel costs, dominate discussion despite resilient travel demand and premium revenue. Traders are divided between concern that fuel and other expenses will keep squeezing margins and optimism that strong bookings and fare increases can offset the pressure.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is drawing attention amid concerns about its heavy debt, costly financing and ability to fund AI infrastructure expansion, alongside a broader pullback in neocloud stocks. Bears warn of refinancing and dilution risks, while bulls point to contracted demand and Nvidia ties; traders also debate whether Goldmans Buy upgrade and ARKs purchases can support a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms

Equity

The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

3 Promising Genomics Stocks in the Spotlight in 2026 

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform

The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The selling was concentrated across several of Ark's ETFs rather than limited to one part of the portfolio.</li><li>ARK Innovation ETF pared its stake in five prominent companies, namely, SpaceX, AMD, Alphabet, Robinhood Markets and Shopify.</li><li>The buying activity was concentrated in ARKG, where Ark added positions across a broad group of biotechnology companies rather than concentrating its purchases in a single stock.</li></ul>Cathie Wood-led Ark Invest reshuffled several of its holdings Friday, selling a number of prominent technology and growth names while adding to a wide range of biotechnology stocks.The trades put some of Ark's better-known holdings on the sell side, including Advanced Micro Devices Inc. (AMD), Alphabet Inc. (GOOG) and Space Exploration Technologies Corp. (SpaceX), while its genomics-focused ARK Genomic Revolution ETF (ARKG) continued to add to biotech companies.<h2 class="st-heading-2">Ark Pares AMD, SPCX, GOOG Stakes</h2>The selling was concentrated across several of Ark's ETFs rather than limited to one part of the portfolio.ARK Innovation ETF (<a class="mention" data-mention="$ARKK" data-symbol-id="ARKK" href="https://stocktwits.com/symbol/ARKK" target="_blank">ARKK</a>) pared its stake in five prominent companies, namely, SpaceX, AMD, Alphabet, Robinhood Markets Inc. (HOOD) and Shopify Inc. (SHOP).The trades extended beyond technology. ARK Blockchain &amp; Fintech Innovation ETF (ARKF) sold the ARK 21Shares Bitcoin ETF (ARKB) and DraftKings Inc. (DKNG), while ARKG reduced positions in Personalis Inc. (PSNL) and CareDx Inc. (CDNA). ARK Space &amp; Defense Innovation ETF (ARKX) sold Iridium Communications Inc. (IRDM).Among the technology names, the transactions included both semiconductor and internet exposure, with AMD, Alphabet and Shopify all appearing among ARKK's sales.<h2 class="st-heading-2">ARKG Adds Across Biotech</h2>The buying activity was concentrated in ARKG, where Ark added positions across a broad group of biotechnology companies rather than concentrating its purchases in a single stock.The purchases included gene-editing companies CRISPR Therapeutics AG (CRSP), Intellia Therapeutics Inc. (NTLA) and Beam Therapeutics Inc. (BEAM).Other companies which saw buying activity from ARKG included Nurix Therapeutics Inc. (NRIX), Guardant Health Inc. (GH), Kymera Therapeutics Inc. (KYMR), Compass Pathways PLC (CMPS), Alamar Biosciences Inc. (ALMR) and Freenome Inc. (FRNM).ARK Autonomous Technology &amp; Robotics ETF (ARKQ) also bought shares of Symbotic Inc. (SYM) and Kodiak AI Inc. (KDK).<a href="https://stocktwits.com/symbol/ARKG">ARKG’s price</a> closed up over 4% in Friday’s regular trading session and rose nearly 0.4% during the after-hours trade. Retail sentiment on Stocktwits around ARKG trended in the ‘bearish’ territory at the time of writing.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-spectrum-deal-raises-asts-value-telecom-stocks/cZxTkNERBnp">SpaceX's Spectrum Deal Could Boost AST SpaceMobile’s Strategic Value — Analyst Calls ASTS 'Natural Satellite Partner' For Carriers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Alamar Biosciences Inc.

Advanced Micro Devices Inc

ARK 21Shares Bitcoin ETF

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARK Innovation ETF

ARK Autonomous Technology & Robotics ETF

ARK Space Exploration & Innovation ETF

Beam Therapeutics Inc

Caredx Inc

COMPASS Pathways

CRISPR Therapeutics AG

DraftKings Inc

Freenome, Inc.

Guardant Health Inc

Alphabet Inc - Ordinary Shares - Class C

Robinhood Markets Inc

Iridium Communications Inc

Kodiak AI Inc. - Ordinary Shares - Class A

Kymera Therapeutics Inc

Nurix Therapeutics Inc

Personalis Inc

SpaceX

Symbotic Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$11.58
Prev Close	$11.42
Open	$11.54
Dividend Yield	0.00%
50-Day Moving Average	$12.25
Beta	1.86
Avg. Volume	4.13M
PE Ratio	-3.45

52-Week High	$27.86
52-Week Low	$7.95
Market Capitalization	$1.6B
EPS (Annual)	-$3.81
Price to Book	2.23
Revenue Per Employee	$179,498.67

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTLA Fundamentals